Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar

Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say. The CEOs of Merck & Co. Inc. MRK, +0.49%, Johnson & Johnson JNJ, -0.11% and Bristol Myers Squibb Co. BMY, -1.50% are set to appear before the Senate Health, Education, Labor and Pensions Committee on Thursday for a hearing examining why U.S. prescription-drug prices are far higher than those in other countries. Merck CEO Robert Davis a ...